%0 Generic
%A de Bono, J. S.
%A Mateo, J.
%A Fizazi, K.
%A Saad, F.
%A Shore, N.
%A Sandhu, S.
%A Chi, K. N.
%A Sartor, O.
%A Agarwal, N.
%A Olmos, D.
%A Thiery-Vuillemin, A.
%A Twardowski, P.
%A Roubaud, G.
%A Ozguroglu, M.
%A Kang, J.
%A Burgents, J.
%A Gresty, C.
%A Corcoran, C.
%A Adelman, C. A.
%A Hussain, M.
%T Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
%D 2020
%@ 0923-7534
%U https://hdl.handle.net/10668/26987
%~